According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

A study on mice with melanoma found that aspirin lowered TXA2 levels, which freed up T cells and allowed them to fight cancer more effectively. However, the lead scientist stressed that long-term ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Tesla has its second straight difficult month in Germany, as data released Wednesday showed that vehicle registrations fell 76% in February in Europe's largest economy. The company has asked the U.S.

Foot Locker's fiscal 2026 earnings guidance sharply misses analysts' expectations. The retailer reported fourth-quarter earnings and sales that narrowly beat estimates. Before joining the discount ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...